Impossible to say. All I know is that confirming efficacy will make them the only company in the world that can actually treat Alzheimer's.
On top of that they have a rock-solid IP portfolio that gives them the exclusive right to use PKC activators in neurodegenerative diseases until 2035 or so. That means at least a decade of no competition whatsoever, not just in Alzheimer's but also for every other indication they get approved for.
People can sell all they want, but personally I'm leaning towards leaving my shares alone until someone acquires the company for a premium and converts my shares into something else.
News 
Market Data 
Discover 
AI
